Pfizer USD 43 billion bid for Seagen to be decided by EU antitrust regulators
Brussels: Pfizer's $43 billion bid for Seagen will be decided by EU antitrust regulators by Oct. 19, a regulatory filing showed on Friday.
U.S. pharmaceutical company Pfizer announced the deal, its biggest, in March for Washington-based Seagen, a pioneer of antibody-drug conjugates, which work like "guided missiles" designed to destroy cancer while sparing healthy cells.
The European Commission can either clear the deal after a preliminary review or it can start a four-month long investigation if it has serious concerns.
Pfizer sought EU antitrust approval on Thursday.
Read also: Pfizer, BioNTech gets USFDA nod for 2023-2024 COVID vaccine
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd